Biofilm of <i>Helicobacter pylori</i>: Life Cycle, Features, and Treatment Options

<i>Helicobacter pylori</i> is a gastric pathogen that infects nearly half of the global population and is recognized as a group 1 carcinogen by the Word Health Organization. The global rise in antibiotic resistance has increased clinical challenges in treating <i>H. pylori</i>...

Full description

Bibliographic Details
Main Authors: Yasmine Elshenawi, Shuai Hu, Skander Hathroubi
Format: Article
Language:English
Published: MDPI AG 2023-07-01
Series:Antibiotics
Subjects:
Online Access:https://www.mdpi.com/2079-6382/12/8/1260
_version_ 1827730613893857280
author Yasmine Elshenawi
Shuai Hu
Skander Hathroubi
author_facet Yasmine Elshenawi
Shuai Hu
Skander Hathroubi
author_sort Yasmine Elshenawi
collection DOAJ
description <i>Helicobacter pylori</i> is a gastric pathogen that infects nearly half of the global population and is recognized as a group 1 carcinogen by the Word Health Organization. The global rise in antibiotic resistance has increased clinical challenges in treating <i>H. pylori</i> infections. Biofilm growth has been proposed to contribute to <i>H. pylori’s chronic</i> colonization of the host stomach, treatment failures, and the eventual development of gastric diseases. Several components of <i>H. pylori</i> have been identified to promote biofilm growth, and several of these may also facilitate antibiotic tolerance, including the extracellular matrix, outer membrane proteins, shifted morphology, modulated metabolism, efflux pumps, and virulence factors. Recent developments in therapeutic approaches targeting <i>H. pylori</i> biofilm have shown that synthetic compounds, such as small molecule drugs and plant-derived compounds, are effective at eradicating <i>H. pylori</i> biofilms. These combined topics highlight the necessity for biofilm-based research in <i>H. pylori</i>, to improve current <i>H. pylori</i>-targeted therapeutic approaches and alleviate relative public health burden. In this review we discuss recent discoveries that have decoded the life cycle of <i>H. pylori</i> biofilms and current biofilm-targeted treatment strategies.
first_indexed 2024-03-11T00:10:12Z
format Article
id doaj.art-12d6fdf746424d0fbd40c615e14764ad
institution Directory Open Access Journal
issn 2079-6382
language English
last_indexed 2024-03-11T00:10:12Z
publishDate 2023-07-01
publisher MDPI AG
record_format Article
series Antibiotics
spelling doaj.art-12d6fdf746424d0fbd40c615e14764ad2023-11-18T23:59:07ZengMDPI AGAntibiotics2079-63822023-07-01128126010.3390/antibiotics12081260Biofilm of <i>Helicobacter pylori</i>: Life Cycle, Features, and Treatment OptionsYasmine Elshenawi0Shuai Hu1Skander Hathroubi2Department of Microbiology and Environmental Toxicology, University of California, Santa Cruz, CA 95064, USADepartment of Microbiology and Environmental Toxicology, University of California, Santa Cruz, CA 95064, USASpartha Medical, CRBS 1 Rue Eugène Boeckel, 67000 Strasbourg, France<i>Helicobacter pylori</i> is a gastric pathogen that infects nearly half of the global population and is recognized as a group 1 carcinogen by the Word Health Organization. The global rise in antibiotic resistance has increased clinical challenges in treating <i>H. pylori</i> infections. Biofilm growth has been proposed to contribute to <i>H. pylori’s chronic</i> colonization of the host stomach, treatment failures, and the eventual development of gastric diseases. Several components of <i>H. pylori</i> have been identified to promote biofilm growth, and several of these may also facilitate antibiotic tolerance, including the extracellular matrix, outer membrane proteins, shifted morphology, modulated metabolism, efflux pumps, and virulence factors. Recent developments in therapeutic approaches targeting <i>H. pylori</i> biofilm have shown that synthetic compounds, such as small molecule drugs and plant-derived compounds, are effective at eradicating <i>H. pylori</i> biofilms. These combined topics highlight the necessity for biofilm-based research in <i>H. pylori</i>, to improve current <i>H. pylori</i>-targeted therapeutic approaches and alleviate relative public health burden. In this review we discuss recent discoveries that have decoded the life cycle of <i>H. pylori</i> biofilms and current biofilm-targeted treatment strategies.https://www.mdpi.com/2079-6382/12/8/1260<i>Helicobacter pylori</i>biofilmsplanktonicantibiotic resistanceextra polymeric substanceabiotic/biotic adhesion
spellingShingle Yasmine Elshenawi
Shuai Hu
Skander Hathroubi
Biofilm of <i>Helicobacter pylori</i>: Life Cycle, Features, and Treatment Options
Antibiotics
<i>Helicobacter pylori</i>
biofilms
planktonic
antibiotic resistance
extra polymeric substance
abiotic/biotic adhesion
title Biofilm of <i>Helicobacter pylori</i>: Life Cycle, Features, and Treatment Options
title_full Biofilm of <i>Helicobacter pylori</i>: Life Cycle, Features, and Treatment Options
title_fullStr Biofilm of <i>Helicobacter pylori</i>: Life Cycle, Features, and Treatment Options
title_full_unstemmed Biofilm of <i>Helicobacter pylori</i>: Life Cycle, Features, and Treatment Options
title_short Biofilm of <i>Helicobacter pylori</i>: Life Cycle, Features, and Treatment Options
title_sort biofilm of i helicobacter pylori i life cycle features and treatment options
topic <i>Helicobacter pylori</i>
biofilms
planktonic
antibiotic resistance
extra polymeric substance
abiotic/biotic adhesion
url https://www.mdpi.com/2079-6382/12/8/1260
work_keys_str_mv AT yasmineelshenawi biofilmofihelicobacterpyloriilifecyclefeaturesandtreatmentoptions
AT shuaihu biofilmofihelicobacterpyloriilifecyclefeaturesandtreatmentoptions
AT skanderhathroubi biofilmofihelicobacterpyloriilifecyclefeaturesandtreatmentoptions